TrialPsychopharmacology2012

Efficacy and safety of the novel α₄β₂ neuronal nicotinic receptor partial agonist ABT-089 in adults with attention-deficit/hyperactivity disorder: a randomized, double-blind, placebo-controlled crossover study.

George Apostol et al.PubMed ↗Publisher ↗

No numbers read from the abstract.